SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sword who wrote (784)3/24/2000 7:51:00 AM
From: ayn rand  Read Replies (1) of 1298
 
FOSTER CITY, Calif., March 24, 2000-Cell Genesys (Nasdaq: CEGE)

CELL GENESYS REPORTS SUCCESSFUL PRECLINICAL STUDIES OF LENTIVIRAL GENE THERAPY FOR HEMOPHILIA A

CEGE today announced that Inder Verma, Ph.D., and colleagues at The Salk Institute have reported the successful use of lentiviral vectors in preclinical studies of hemophilia A, an inherited bleeding disorder. In addition, Flavia Borellini, Ph.D. and colleagues at Cell Genesys reported the successful development of the scaleable manufacturing technology for lentiviral vectors required for clinical studies in hemophilia and other serious diseases. These presentations were made in Washington D.C. at the Third Workshop on Gene Therapies for Hemophilia sponsored by the National Hemophilia Foundation.

cellgenesys.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News